Beta-adrenoblockers in coronary heart disease patients. Evidencebased medicine data

High effectiveness and safety of beta-adrenoblockers (BB) in patients with coronary heart disease (CHD) have been proven by manifold clinical trials. BB are effective and safe, provided dose regimen is correct and contraindications are taken into account. BB significantly reduce total mortality and sudden cardiac death risk in CHD patients

Systemic enzyme therapy and clinical and hemorheological parameters in coronary heart disease patients with effort angina

This study is devoted to systemic enzyme therapy (wobenzym and phlogenzym) influence on hemostasis, hemorheology, and clinical course of disease inpatients (n=54) with Functional Class II-III effort angina, receiving complex therapy. Systemic enzyme therapy improved blood rheology due to decreased red and white blood cell aggregation, increased elasticity of red blood cell membrane; optimized fibrinolysis and hemocoagulation systems' status; improved angina clinical course and quality of life. Including wobenzym and phlogenzym into complex therapy ofFC II-III effort angina patients is clinically rational, effective, and safe